SCHEMBL14720239

SCHEMBL14720239

COC(=O)CC(c1ccc(Br)cc1F)N1CCC2(CC1)CN(C1CC1)C(=O)CO2

nearest known ligand 0.36

Predicted protein targets (top 19)

geneUniProtsupporting neighboursconfidence
FASN P49327 4/20 0.36
MEN1 O00255 1/20 0.35
LMNA P02545 1/20 0.35
KMT2A Q03164 1/20 0.35
OPRM1 P35372 4/20 0.33
CNR1 P21554 1/20 0.32
CNR2 P34972 1/20 0.32
P2RX7 Q99572 1/20 0.30
HSD11B1 P28845 1/20 0.30
AADAT Q8N5Z0 1/20 0.30
ACKR3 P25106 1/20 0.30
CCR5 P51681 1/20 0.30
FPR3 P25089 1/20 0.30
FPR2 P25090 1/20 0.30
ALDH1A1 P00352 1/20 0.30
GAA P10253 1/20 0.30
MAPT P10636 1/20 0.30
TDP1 Q9NUW8 1/20 0.30
L3MBTL1 Q9Y468 1/20 0.30

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL14720419 0.88 FASN (0.36) FASNMEN1LMNAKMT2AOPRM1
SCHEMBL14720433 0.86 FASN (0.36) FASNMEN1LMNAKMT2AOPRM1
SCHEMBL14720346 0.86 HSD11B1 (0.36) FASNHSD11B1
SCHEMBL14720839 0.84 FASN (0.34) FASNMEN1LMNAKMT2AOPRM1
SCHEMBL14720191 0.83 OPRM1 (0.46) FASNOPRM1HSD11B1
SCHEMBL14720222 0.82 FASN (0.56) FASN
SCHEMBL14720420 0.82 FASN (0.36) FASNOPRM1CNR1CNR2P2RX7
SCHEMBL14720349 0.82 FASN (0.38) FASNOPRM1CNR1CNR2HSD11B1
SCHEMBL14720613 0.81 FASN (0.37) FASNOPRM1CNR1CNR2HSD11B1
SCHEMBL14720292 0.79 FASN (0.35) FASN

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2744333-B1 FATTY ACID SYNTHASE INHIBITORS GLAXOSMITHKLINE IP NO 2 LTD (GB) 2016-10-05 EP disclosed
US-9084794-B2 Fatty acid synthase inhibitors GLAXOSMITHKLINE INTELLECTUAL PROPERTY (NO. 2) LIMITED (GB) 2015-07-21 US disclosed
US-20140194415-A1 FATTY ACID SYNTHASE INHIBITORS GlaxoSmithKline Intellectual Property (No2) Limite (GB) 2014-07-10 US disclosed
EP-2744333-A1 FATTY ACID SYNTHASE INHIBITORS Glaxosmithkline Intellectual Property (No. 2) Limited (GB) 2014-06-25 EP disclosed
WO-2013028447-A1 FATTY ACID SYNTHASE INHIBITORS GLAXOSMITHKLINE LLC (US) 2013-02-28 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20140194415-A1 FATTY ACID SYNTHASE INHIBITORS FASN, FADS2, FADS1 FASN 1/4885MEN1 4632/4885LMNA 1938/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.